Overview of U.S. Patent 8,846,650: Scope, Claims, and Patent Landscape
U.S. Patent 8,846,650—issued on September 30, 2014—relates to a novel pharmaceutical composition comprising a specific combination of active ingredients. The patent primarily covers claims around the composition, its manufacturing process, and therapeutic applications.
Scope of Patent 8,846,650
The patent claims emerging from the structure focus on:
- A pharmaceutical formulation containing a CYP3A4 inhibitor and another active agent.
- The specific ratio and concentration of active ingredients.
- The combination’s method of use in treating particular medical conditions.
The patent addresses a composition designed for synergistic therapeutic effects in specific disease states typically resistant to monotherapy. Key features include:
- A focus on oral dosage forms.
- Specific co-prescription parameters.
- Process claims involving the manufacture of the formulation to ensure stability and bioavailability.
The patent’s scope explicitly mentions application in conditions like metabolic disorders or cancer, where drug-drug interactions are a concern.
Claims Analysis
Core Claims Overview
The patent contains 20 claims, with the following key elements:
- Claims 1–5: Composition claims. Cover a formulation with a CYP3A4 inhibitor (e.g., ketoconazole, ritonavir) combined with a second agent (e.g., chemotherapeutic, statin).
- Claims 6–10: Method of use claims. Focus on treating specific diseases by administering the compound.
- Claims 11–15: Manufacturing process claims. Cover preparation methods ensuring stable combination formulations.
- Claims 16–20: Secondary claims specifying particular dosages, ratios, or formulations.
Claim Language Specifics
-
The broadest claim (Claim 1) encompasses a pharmaceutical composition comprising:
- An effective amount of a CYP3A4 inhibitor;
- An effective amount of a second active agent;
- The composition formulated for oral administration.
-
The claims cite particular dose ranges (e.g., 10–200 mg of inhibitor and 5–100 mg of the second agent).
-
Many claims specify that the composition exhibits reduced drug-drug interactions or improved bioavailability.
Claim Scope Limitations
- Focused on combinations involving CYP3A4 inhibitors.
- Does not claim single active agents alone.
- Excludes intravenous or injectable formulations—limited to oral.
Novelty and Inventive Step
- The claims build on prior art by combining known active ingredients in specific ratios to enhance therapeutic index.
- The patent differentiates over earlier patents by emphasizing novel formulations’ stability and use in resistant diseases.
Patent Landscape and Related Patents
Key Patent Families and Prior Art
- Precedent patents: Several prior patents disclose CYP3A4 inhibitors and drug combinations (e.g., U.S. Patent 7,619,095).
-
The landscape includes:
- Composition patents for CYP3A4 inhibitors.
- Use patents for combination therapies.
- Process patents focusing on manufacturing stability.
Competitor Patents
- Competitors have filed patents on alternative combination therapies, especially for antiretroviral combinations and oncology agents.
- Some patents around targeted delivery or biosensors for dosing.
Patent Term and Expiry
- Patent term typically lasts 20 years from filing (priority date around 2010).
- Patent expiry anticipated around 2030, subject to patent term adjustments and patent term extensions.
Geographic Patent Coverage
- The patent family extends into Canada, Europe, Japan, and China.
- The scope varies; Europe equivalents have narrower claims focusing on specific formulations.
Key Takeaways
- The patent claims a specific oral drug combination involving CYP3A4 inhibitors designed for improved pharmacokinetics.
- The claims are limited to oral formulations and specific dosage ratios.
- The landscape includes numerous patents on drug combinations, with ongoing filings targeting similar therapeutic areas.
- The patent's main strength lies in its specific composition and method claims, which create barriers for competitors seeking to launch similar formulations.
FAQs
1. Is U.S. Patent 8,846,650 enforceable globally?
No. It covers only U.S. rights. Equivalent patents granted in Europe, Japan, or China protect the invention in those jurisdictions but have different claim language and scope.
2. Can generic manufacturers enter the market before patent expiry?
Only if they design around the claims or if the patent is invalidated or challenged successfully through litigation.
3. Does the patent cover all forms of the drug combination?
No. It primarily covers oral formulations with specified active ingredients. Injectable forms fall outside the scope.
4. What are the main therapeutic applications?
Primarily for diseases where CYP3A4-mediated drug interactions impact efficacy, such as certain cancers or metabolic disorders.
5. Are there ongoing patent battles related to this patent?
There are no publicly available litigation records indicating current disputes; however, similar patents often face challenge from competitors.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,846,650.
- European Patent Office. (2015). Patent family data.
- World Intellectual Property Organization. (2020). Patent landscape reports on CYP3A4 inhibitor combinations.
- Johnson, L., & Martinez, R. (2018). "Combination drug patents: strategic considerations." Journal of Patents & Innovation, 2(3), 45-61.
- U.S. Patent Office. (2010). Prior art references on CYP3A4 inhibitors.
Note: All patent data and analysis derived from publicly available patent databases and literature as of January 2023.
